SCHEMBL4925329

SCHEMBL4925329

C[C@@H](NC(=O)c1ccc(-c2ccnc(N)n2)s1)c1cccc(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 9/20 0.52
PRKACA P17612 2/20 0.52
GSK3A P49840 2/20 0.52
GSK3B P49841 2/20 0.52
RPS6KA3 P51812 2/20 0.52
AURKB Q96GD4 2/20 0.52
CLK4 Q9HAZ1 2/20 0.52
CHEK1 O14757 1/20 0.52
AURKA O14965 1/20 0.52
MAP4K4 O95819 1/20 0.52
GRK5 P34947 1/20 0.52
CSNK1A1 P48729 1/20 0.52
CDK8 P49336 1/20 0.52
PRKX P51817 1/20 0.52
PRKCQ Q04759 1/20 0.52
ACVR1 Q04771 1/20 0.52
HPGDS O60760 4/20 0.47
AKT3 Q9Y243 4/20 0.46
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929904 0.88 HDAC3 (0.57) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4924499 0.88 HDAC3 (0.57) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4923121 0.87 ROCK1 (0.70) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4927771 0.87 ROCK1 (0.70) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4929158 0.87 ROCK1 (0.70) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4929103 0.86 ROCK1 (0.48) ROCK1PRKACAGSK3AGSK3BRPS6KA3
SCHEMBL4930326 0.78 DYRK1A (0.55) ROCK1HPGDSAKT3ROCK2
SCHEMBL4931327 0.77 ROCK1 (0.52) ROCK1HPGDSAKT3ROCK2ALDH1A1
SCHEMBL4927755 0.77 ROCK1 (0.52) ROCK1HPGDSAKT3ROCK2ALDH1A1
SCHEMBL13992686 0.76 AKT3 (0.52) AKT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 US disclosed
EP-1708697-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-11-28 EP disclosed
EP-1708697-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 EP disclosed
WO-2005074642-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293716-A1 Chemical Compounds CYP11B2, CYP11B1, REN ROCK1 968/4885PRKACA 3211/4885GSK3A 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.